title: Survival rates of familial and sporadic prostate cancer patients.
abstract: OBJECTIVE
  To compare cancer-specific survival rates for familial and sporadic prostate cancer patients.
  
  
  METHODS
  Gleason score and age at diagnosis of familial group and sporadic group were compared by χ(2) and t-test. Cancer-specific survival rates were analyzed by the Kaplan - Meier method and compared by log-rank test. Statistically significant level was set at p < 0.05.
  
  
  RESULTS
  Among 1175 prostate cancer patients, familial group consisted of 215 (18.3%) patients, the sporadic group consisted of 960 (81.7%) patients. The familial group patient's mean age at diagnosis (58.9 years old, 95% confidence interval (CI) 57.8-60.1) was significantly younger than that of sporadic group patients (67.2 years old, 95% CI 66.7-67.6) (p < 0.0001). Comparing Gleason score between familial group and sporadic group revealed no statistically significant difference. The analysis showed that 92% (95% CI 0.88-0.97) of familial group patients had a 10-year cancer-specific survival rates, which was a significantly better outcome than that of sporadic group with 69% (95% CI 0.60-0.78) 10-year cancer-specific survival rates (p = 0.0237).
  
  
  CONCLUSIONS
  The study data demonstrate statistically significant difference between familial group and sporadic group concerning age and cancer-specific survival rates, but not Gleason score.
authors.affiliation: Institute of Oncology, Riga Stradins University, Riga LV-1007, Latvia.
authors.forename: J
authors.initials: J
authors.lastname: Plonis
authors.affiliation: Institute of Oncology, Riga Stradins University, Riga LV-1007, Latvia.
authors.forename: M
authors.initials: M
authors.lastname: Nakazawa-Miklasevica
authors.affiliation: Center of Urology, Pauls Stradins University Hospital, Riga LV-1007, Latvia.
authors.forename: A
authors.initials: A
authors.lastname: Malevskis
authors.affiliation: Institute of Oncology, Riga Stradins University, Riga LV-1007, Latvia.
authors.forename: P
authors.initials: P
authors.lastname: Vaganovs
authors.affiliation: Center for Disease Prevention and Control, Riga LV-1007, Latvia.
authors.forename: S
authors.initials: S
authors.lastname: Pildava
authors.affiliation: Institute of Oncology, Riga Stradins University, Riga LV-1007, Latvia.
authors.forename: E
authors.initials: E
authors.lastname: Vjaters
authors.affiliation: Institute of Oncology, Riga Stradins University, Riga LV-1007, Latvia.
authors.forename: J
authors.initials: J
authors.lastname: Gardovskis
authors.affiliation: Institute of Oncology, Riga Stradins University, Riga LV-1007, Latvia.
authors.forename: E
authors.initials: E
authors.lastname: Miklasevics
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000401:mortality*